BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23033890)

  • 1. Is there a role for tirapazamine in the treatment of cervical cancer?
    Ghatage P; Sabagh H
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1589-97. PubMed ID: 23033890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirapazamine: from bench to clinical trials.
    Marcu L; Olver I
    Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tirapazamine-cisplatin: the synergy.
    Gatzemeier U; Rodriguez G; Treat J; Miller V; von Roemeling R; Viallet J; Rey A
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):15-7. PubMed ID: 9647615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirapazamine: a novel agent targeting hypoxic tumor cells.
    Reddy SB; Williamson SK
    Expert Opin Investig Drugs; 2009 Jan; 18(1):77-87. PubMed ID: 19053884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
    Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer.
    Aghajanian C; Brown C; O'flaherty C; Fleischauer A; Curtin J; Roemeling R; Spriggs DR
    Gynecol Oncol; 1997 Nov; 67(2):127-30. PubMed ID: 9367694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
    Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
    J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
    Denny WA; Wilson WR
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current methods of chemoradiotherapy for locally advanced cervical cancer. Options for reduction of side-effects].
    Póti Z; Mayer A
    Orv Hetil; 2013 May; 154(21):803-9. PubMed ID: 23692874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
    Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
    J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tirapazamine: laboratory data relevant to clinical activity.
    Brown JM; Wang LH
    Anticancer Drug Des; 1998 Sep; 13(6):529-39. PubMed ID: 9755717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiation for cervical cancer: what should we do next?
    Toita T
    Int J Clin Oncol; 2006 Aug; 11(4):253-5. PubMed ID: 16937297
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioreductive drugs: from concept to clinic.
    McKeown SR; Cowen RL; Williams KJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan in cervical cancer.
    Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
    Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.
    Maluf FC; Leiser AL; Aghajanian C; Sabbatini P; Pezzulli S; Chi DS; Wolf JK; Levenback C; Loh E; Spriggs DR
    Int J Gynecol Cancer; 2006; 16(3):1165-71. PubMed ID: 16803501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
    Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
    J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer.
    Rischin D; Narayan K; Oza AM; Mileshkin L; Bernshaw D; Choi J; Hicks R; McClure B; Fyles A
    Int J Gynecol Cancer; 2010 Jul; 20(5):827-33. PubMed ID: 20606530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
    Gandara DR; Lara PN; Goldberg Z; Le QT; Mack PC; Lau DH; Gumerlock PH
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):102-9. PubMed ID: 11894020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.